(E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one
(E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one Basic information
- Product Name:
- (E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one
- Synonyms:
-
- (E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one
- CS-510
- E2012;E 2012;E-2012
- (3E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-2-piperidone
- E-2012;E2012
- 2-Piperidinone, 1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylene]-, (3E)-
- (S,E)-1-(1-(4-fluorophenyl)ethyl)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)piperidin-2-one
- 1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[[3-Methoxy-4-(4-Methyl-1H-iMidazol-1-yl)phenyl]Methylene]-
- CAS:
- 870843-42-8
- MF:
- C25H26FN3O2
- MW:
- 419.49
- Product Categories:
-
- API intermediates
- Mol File:
- 870843-42-8.mol
(E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one Chemical Properties
- Boiling point:
- 649.2±55.0 °C(Predicted)
- Density
- 1.19±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMF: 10mg/mL; DMSO: 10mg/mL; DMSO:PBS (pH 7.2) (1:3): 0.25mg/mL; Ethanol: 10mg/mL
- pka
- 5.67±0.61(Predicted)
- form
- Powder
- color
- Light yellow to yellow
- InChIKey
- PUOAETJYKQITMO-LANLRWRYSA-N
- SMILES
- N1([C@H](C2=CC=C(F)C=C2)C)CCC/C(=C\C2=CC=C(N3C=NC(C)=C3)C(OC)=C2)/C1=O
(E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one Usage And Synthesis
Uses
E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat[1].
in vivo
In vivo lenticular concentration of E 2012 after 13-week repeated dose with cataract was well above those where inhibition is observed in vitro. E 2012 induces cataract in the rat by inhibiting DHCR24 at the final step of cholesterol synthesis with associated elevation in desmosterol within the lens, preceded by desmosterol changes that would serve as a predictive safety biomarker for lenticular opacity[2].
storage
Store at -20°C
References
[1] Nakano-Ito K, et al. E2012-induced cataract and its predictive biomarkers. Toxicol Sci. 2014 Jan;137(1):249-58. DOI:10.1093/toxsci/kft224
[2] Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K.Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.J Alzheimers Dis. 2010;21(3):1005-12. DOI:10.3233/JAD-2010-100573
(E)-1-[(1S)-1-(4-Fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-oneSupplier
- Tel
- 021-20242659 18930833303
- Sales@changyanchem.cn
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 001-857-928-2050 or 1-888-588-9418
- sales@chemreagents.com
- Tel
- 0086-21-58956006
- Tel
- 0731-85526065 13308475853
- ivy@hnhbsj.com